CDER New February 4, 2020

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/promotional-labeling-and-advertising-considerations-prescription-biological-reference-and-biosimilar?utm_campaign=CDER%20New%2002%2F04%2F2020&utm_medium=email&utm_source=Eloqua&elqTrackId=7f6349476f574ce683ee252da3c26344&elq=f1e354dc37d64f188bda7fbe6bac15a5&elqaid=11116&elqat=1&elqCampaignId=9333

Updated Monday through Friday

• Drug Firm Annual Registration Status
• Drug Firm Annual Registration Status Download File 
• National Drug Code Directory
• NDC Unfinished Drugs Excluded Database File 
• NDC Database Excluded Packages and Products 
• Wholesale Distributor and Third-Party Logistics Providers Reporting  

February 3, 2020

• Laboratory Tests | Metformin
• Updates and Press Announcements on NDMA in Metformin
• Drug Trials Snapshots: JEUVEAU
• Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry